Refine
Year of publication
Document Type
- Article (5135)
- Doctoral Thesis (1476)
- Part of Periodical (210)
- Conference Proceeding (164)
- Preprint (159)
- Book (85)
- Contribution to a Periodical (63)
- Review (38)
- Working Paper (22)
- Part of a Book (16)
Language
Keywords
- inflammation (80)
- COVID-19 (58)
- SARS-CoV-2 (48)
- apoptosis (38)
- glioblastoma (38)
- Inflammation (37)
- cancer (37)
- breast cancer (34)
- autophagy (29)
- prostate cancer (26)
Institute
- Medizin (7388) (remove)
Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis
(2015)
High polo-like kinase 1 (PLK1) expression has been linked to poor outcome in neuroblastoma (NB), indicating that it represents a relevant therapeutic target in this malignancy. Here, we identify a synergistic induction of apoptosis by the PLK1 inhibitor BI 2536 and vinca alkaloids in NB cells. Synergistic drug interaction of BI 2536 together with vincristine (VCR), vinblastine (VBL) or vinorelbine (VNR) is confirmed by calculation of combination index (CI). Also, BI 2536 and VCR act in concert to reduce long-term clonogenic survival. Importantly, BI 2536 significantly enhances the antitumor activity of VCR in an in vivo model of NB. Mechanistically, BI 2536/VCR co-treatment triggers prolonged mitotic arrest, which is necessary for BI 2536/VCR-mediated apoptosis, since pharmacological inhibition of mitotic arrest by the CDK1 inhibitor RO-3306 significantly reduces cell death. Prolonged mitotic arrest leads to phosphorylation-mediated inactivation of BCL-2 and BCL-XL as well as downregulation of MCL-1, since inhibition of mitotic arrest by RO-3306 also prevents phosphorylation of BCL-2 and BCL-XL and MCL-1 downregulation. This inactivation of antiapoptotic BCL-2 proteins promotes activation of BAX and BAK, cleavage of caspase-9 and -3 and caspase-dependent apoptosis. Engagement of the mitochondrial pathway of apoptosis is critically required for BI 2536/VCR-induced apoptosis, since ectopic expression of a non-degradable MCL-1 phospho-mutant, BCL-2 overexpression or BAK knockdown significantly reduce BI 2536/VCR-mediated apoptosis. Thus, PLK1 inhibitors may open new perspectives for chemosensitization of NB.
Die politische Steuerung des Krankenhaussektors hat sich in den vergangenen anderthalb Jahrzehnten nachhaltig verändert. Das Gesundheitsstrukturgesetz von 1992 markiert einen gesundheitspolitischen Paradigmenwechsel, mit dem verstärkt wettbewerbliche Steuerungsinstrumente in das Gesundheitswesen eingeführt wurden. Auch im stationären Sektor ersetzen bzw. ergänzen wettbewerbliche Instrumente korporatistische Arrangements. Die Gegenüberstellung der politischen Steuerung des Krankenhaussektors vor 1992 mit der Situation nach der Gesundheitsreform 2007 verdeutlicht, dass auf den Feldern Leistungserbringung, Vergütung und Qualitätssicherung sukzessive ein neues Steuerungsmodell entstanden ist. Dieses zeichnet sich durch eine gewachsene Komplexität, eine Zunahme von Steuerungsaktivitäten und eine Neujustierung des Verhältnisses staatlicher bzw. korporatistischer Steuerung einerseits und wettbewerblicher Steuerung andererseits aus. Dort, wo es um allokative Entscheidungen geht, werden korporatistische Elemente durch wettbewerbliche ersetzt. Auf anderen Regulierungsfelder bleibt der Korporatismus dagegen erhalten. Der Staat als „architect of political order“ (Anderson) hat diese Transformation herbeigeführt, sieht sich allerdings zunehmend mit dem Widerspruch zwischen einer bedarfsorientierten Krankenhausplanung und Investitionsfinanzierung auf Landesebene und einer Leistungsverteilung über den Wettbewerb konfrontiert.
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.
Macrophages exposed to the Th2 cytokines interleukin (IL) IL-4 and IL-13 exhibit a distinct transcriptional response, commonly referred to as M2 polarization. Recently, IL-4-induced polarization of murine bone marrow-derived macrophages (BMDMs) has been linked to acetyl-CoA levels through the activity of the cytosolic acetyl-CoA-generating enzyme ATP-citrate lyase (ACLY). Here, we studied how ACLY regulated IL-4-stimulated gene expression in human monocyte-derived macrophages (MDMs). Although multiple ACLY inhibitors attenuated IL-4-induced target gene expression, this effect could not be recapitulated by silencing ACLY expression. Furthermore, ACLY inhibition failed to alter cellular acetyl-CoA levels and histone acetylation. We generated ACLY knockout human THP-1 macrophages using CRISPR/Cas9 technology. While these cells exhibited reduced histone acetylation levels, IL-4-induced gene expression remained intact. Strikingly, ACLY inhibitors still suppressed induction of target genes by IL-4 in ACLY knockout cells, suggesting off-target effects of these drugs. Our findings suggest that ACLY may not be the major regulator of nucleocytoplasmic acetyl-CoA and IL-4-induced polarization in human macrophages. Furthermore, caution should be warranted in interpreting the impact of pharmacological inhibition of ACLY on gene expression.
Chronic viral hepatitis is associated with substantial morbidity and mortality worldwide. The aim of our study was to assess the ability of point shear‐wave elastography (pSWE) using acoustic radiation force impulse imaging for the prediction of the following liver‐related events (LREs): new diagnosis of HCC, liver transplantation, or liver‐related death (hepatic decompensation was not included as an LRE). pSWE was performed at study inclusion and compared with liver histology, transient elastography (TE), and serologic biomarkers (aspartate aminotransferase to platelet ratio index, Fibrosis‐4, FibroTest). The performance of pSWE and TE to predict LREs was assessed by calculating the area under the receiver operating characteristic curve and a Cox proportional‐hazards regression model. A total of 254 patients with a median follow‐up of 78 months were included in the study. LRE occurred in 28 patients (11%) during follow‐up. In both patients with hepatitis B virus and hepatitis C virus (HCV), pSWE showed significant correlations with noninvasive tests and TE, and median pSWE and TE values were significantly different between patients with LREs and patients without LREs (both P < 0.0001). In patients with HCV, the area under the receiver operating characteristic curve for pSWE and TE to predict LREs were comparable: 0.859 (95% confidence interval [CI], 0.747‐0.969) and 0.852 (95% CI, 0.737‐0.967) (P = 0.93). In Cox regression analysis, pSWE independently predicted LREs in all patients with HCV (hazard ratio, 17.9; 95% CI, 5.21‐61‐17; P < 0.0001) and those who later received direct‐acting antiviral therapy (hazard ratio, 17.11; 95% CI, 3.88‐75.55; P = 0.0002). Conclusion: Our study shows good comparability between pSWE and TE. pSWE is a promising tool for the prediction of LREs in patients with viral hepatitis, particularly those with chronic HCV. Further studies are needed to confirm our data and assess their prognostic value in other liver diseases.
Insertion of bone substitution materials accelerates healing of osteoporotic fractures. Biodegradable materials are preferred for application in osteoporotic patients to avoid a second surgery for implant replacement. Degraded implant fragments are often absorbed by macrophages that are removed from the fracture side via passage through veins or lymphatic vessels. We investigated if lymphatic vessels occur in osteoporotic bone defects and whether they are regulated by the use of different materials. To address this issue osteoporosis was induced in rats using the classical method of bilateral ovariectomy and additional calcium and vitamin deficient diet. In addition, wedge-shaped defects of 3, 4, or 5 mm were generated in the distal metaphyseal area of femur via osteotomy. The 4 mm defects were subsequently used for implantation studies where bone substitution materials of calcium phosphate cement, composites of collagen and silica, and iron foams with interconnecting pores were inserted. Different materials were partly additionally functionalized by strontium or bisphosphonate whose positive effects in osteoporosis treatment are well known. The lymphatic vessels were identified by immunohistochemistry using an antibody against podoplanin. Podoplanin immunopositive lymphatic vessels were detected in the granulation tissue filling the fracture gap, surrounding the implant and growing into the iron foam through its interconnected pores. Significant more lymphatic capillaries were counted at the implant interface of composite, strontium and bisphosphonate functionalized iron foam. A significant increase was also observed in the number of lymphatics situated in the pores of strontium coated iron foam. In conclusion, our results indicate the occurrence of lymphatic vessels in osteoporotic bone. Our results show that lymphatic vessels are localized at the implant interface and in the fracture gap where they might be involved in the removal of lymphocytes, macrophages, debris and the implants degradation products. Therefore the lymphatic vessels are involved in implant integration and fracture healing.
Background: While the incidence and aspects of pneumonia in ICU patients has been extensively discussed in the literature, studies on the occurrence of pneumonia in severely injured patients are rare. The aim of the present study is to elucidate factors associated with the occurrence of pneumonia in severely injured patients with thoracic trauma.
Setting: Level-I University Trauma Centres associated with the TraumaRegister DGU®.
Methods: A total of 1162 severely injured adult patients with thoracic trauma documented in the TraumaRegister DGU® (TR-DGU) were included in this study. Demographic data, injury severity, duration of mechanical ventilation (MV), duration of ICU stay, occurrence of pneumonia, bronchoalveolar lavage, aspiration, pathogen details, and incidences of mortality were evaluated. Statistical evaluation was performed using SPSS (Version 25.0, SPSS, Inc.) software.
Results: The overall incidence of pneumonia was 27.5%. Compared to patients without pneumonia, patients with pneumonia had sustained more severe injuries (mean ISS: 32.6 vs. 25.4), were older (mean age: 51.3 vs. 47.5) and spent longer periods under MV (mean: 368.9 h vs. 114.9 h). Age, sex (male), aspiration, and duration of MV were all independent predictors for pneumonia occurrence in a multivariate analysis. The cut-off point for duration of MV that best discriminated between patients who would and would not develop pneumonia during their hospital stay was 102 h. The extent of thoracic trauma (AISthorax), ISS, and presence of pulmonary comorbidities did not show significant associations to pneumonia incidence in our multivariate analysis. No significant difference in mortality between patients with and without pneumonia was observed.
Conclusions: Likelihood of pneumonia increases with age, aspiration, and duration of MV. These parameters were not found to be associated with differences in outcomes between patients with and without pneumonia. Future studies should focus on independent parameters to more clearly identify severely injured subgroups with a high risk of developing pneumonia.
Level of evidence: Level II - Retrospective medical record review.
Nierentransplantierte Patienten haben im Vergleich zu einer altersgleichen Bevölkerung ein 10-fach erhöhtes Risiko an kardiovaskulären Erkrankungen zu versterben. Graff et al fanden in einer dieser Arbeit vorangegangenen Untersuchung heraus, dass Thrombozyten nierentransplantierter Patienten unter immunsuppressiver Monotherapie voraktiviert sind, verglichen zu einer aus Hypertonikern bestehenden Kontrollgruppe. Des weiteren scheinen „neuere“ Immunsuppressiva wie Tacrolimus (TAC) Thrombozytenaktivierungsmarker weniger stark zu beeinflussen als „ältere“ wie Cyclosporin (CsA). Ziel dieser Arbeit war es den Einfluss einer antithrombozytären Therapie mit Clopidogrel bei nicht antiaggregatorisch vorbehandelten nierentransplantierten Patienten – Gruppe 1 (TAC, n=17) und Gruppe 2 (CsA, n=17) und nierentransplantierten Patienten mit ASS-Dauermedikation – Gruppe 3 (TAC, n=15) und Gruppe 4 (CsA, n=18), welche im Rahmen der Studie auf Clopidogrel umgestellt worden sind, herauszufinden. Alle Patienten wurden vor (V1) und nach einer vierwöchigen Clopidogrel – Therapie (V2) untersucht. Hierzu wurden Parameter, die eine Thrombozytenaktivierung widerspiegeln wie der Degranulationsmarker CD62, der aktivierte GPIIb/IIIa-Rezeptor (PAC1) sowie die Bildung von Plättchen-Leukozyten Aggregaten (CD41) untersucht. Plättchen-Leukozyten Aggregate (PLAs) akkumulieren an Orten mit Gefäßverletzungen und tragen so zu Entzündungsreaktionen und Thrombosen bei. Die Thrombozytenfunktion (CD62, PAC1) und die Formation von PLAs (CD41, CD11b) wurden vor Beginn der Clopidogrel – Therapie (V1, Gruppe 3 und 4 unter ASS – Therapie) sowie nach vierwöchiger Clopidogrel – Behandlung (V2) durchflusszytometrisch und aggregometrisch untersucht. Bei V1 wiesen CsA behandelte Patienten (Gruppe 2) signifikant (p<0,05) höhere Thrombozytenaktivierungsmarker auf als mit TAC behandelte Patienten: CD62 (185 [112-223] vs. 110 [84-173], median [1Q-3Q]), PAC1 (27 [26-38] vs. 15 [12-35]) und PLA (430 [342-769] vs. 237 [177-510]). Nach vierwöchiger Clopidogrel – Therapie (V2) kam es zu einer signifikanten Reduktion der untersuchten Parametern: CD62 (95 [82-123] Gruppe 2, 71 [56-94] Gruppe 1), PAC1 (15 [8-22] Gruppe 2, 12 [3-15] group 1), PLA (269 [225-472] Gruppe 2, 194 [159-275] Gruppe 1). Bei nierentransplantierten Patienten mit vorheriger ASS – Comedikation (Gruppe 3 und 4) konnte hinsichtlich der Thrombozytenaktivierung zwischen CsA und TAC bei V1 kein signifikanter Unterschied festgestellt werden. Es ließ sich allerdings ein Trend zugunsten TAC ablesen: CD62 (165 [96-289] vs. 111 [73-156]), PAC1 (19 [12-39] vs. 14 [8-32]), und PLA (437 [232-852] vs. 282 [164-471]). Die Umstellung von ASS auf Clopidogrel führte bei CsA behandelten Patienten (Gruppe 4) zu einer signifikanten Reduktion von CD62, PAC1 und der Formation von PLAs bei V2. TAC behandelten Patienten zeigten dagegen nur eine signifikante Abnahme des PAC1-Markers; für CD62 und PLAs wurden zwar bei V2 niedrigere Werte als bei V1 gemessen, allerdings erreichten die Unterschiede keine statistische Signifikanz: CD62 (90 [45-139] Gruppe 4, 67 [51-116] Gruppe 3), PAC1 (11 [7-19] Gruppe 4, 10 [5-20] Gruppe 3), PLA (285 [186-470] Gruppe 4, 250 [143-298] Gruppe 3). Zusammenfassend lässt sich ableiten, dass CsA die Thrombozytenaktivierung sowie die Formation von PLAs stärker negativ beeinflusst als TAC. Clopidogrel scheint diesen Vorgang effektiver als Aspirin zu hemmen.